Health-related quality of life after first-line anti-cancer treatments for advanced non-small cell lung cancer in clinical practice.

Purpose: This study attempted to compare changes in the Quality-of-Life (QoL) scores after three different first-line anti-cancer treatments for advanced non-small cell lung cancer (NSCLC) in a real-world clinical setting.Patients and Methods: From May 2011 to December 2013, we prospectively measure...

Descripción completa

Detalles Bibliográficos
Publicado en:Quality of Life Research Vol. 25; no. 6; pp. 1441 - 1450
Autores principales: Yang, Szu-Chun, Lai, Wu-Wei, Hsiue, Tzuen-Ren, Su, Wu-Chou, Lin, Cheng-Kuan, Hwang, Jing-Shiang, Wang, Jung-Der
Formato: research Journal Article
Publicado: Springer Nature Jun2016
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=115397988&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 115397988
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        09629343
        GPQ
      jtl: Quality of Life Research
      issn: 09629343
      maglogo: N
    pubinfo:
      dt: Jun2016
      vid: 25
      iid: 6
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        115397988
        115397988
        NLM26545386
        115397988
        10.1007/s11136-015-1174-5
        NLM26545386
        115397988
      ppf: 1441
      ppct: 9
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Health-related quality of life after first-line anti-cancer treatments for advanced non-small cell lung cancer in clinical practice.
      aug:
        au:
          Yang, Szu-Chun
          Lai, Wu-Wei
          Hsiue, Tzuen-Ren
          Su, Wu-Chou
          Lin, Cheng-Kuan
          Hwang, Jing-Shiang
          Wang, Jung-Der
        affil: Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138 Sheng Li Road Tainan 704 Taiwan
      sug:
        subj:
          Antineoplastic Agents Therapeutic Use
          Quality of Life Psychosocial Factors
          Lung Neoplasms Drug Therapy
          Carcinoma, Non-Small-Cell Lung Drug Therapy
          Prospective Studies
          Deoxycytidine Therapeutic Use
          Human
          Male
          Heterocyclic Compounds Therapeutic Use
          World Health Organization
          Female
          Deoxycytidine
          Sickness Impact Profile
          Aged
          Middle Age
          Platinum Administration and Dosage
          Validation Studies
          Comparative Studies
          Evaluation Research
          Multicenter Studies
          Interview Guides
          Questionnaires
          Aged: 65+ years
          Middle Aged: 45-64 years
          Male
          Female
      ab: Purpose: This study attempted to compare changes in the Quality-of-Life (QoL) scores after three different first-line anti-cancer treatments for advanced non-small cell lung cancer (NSCLC) in a real-world clinical setting.Patients and Methods: From May 2011 to December 2013, we prospectively measured the QoL scores of patients with locally advanced or metastatic NSCLC using the World Health Organization Quality-of-Life-Brief (WHOQOL-BREF) questionnaire. Each QoL measurement was matched by age and sex with one healthy referent from the National Health Interview Survey. Dynamic changes in patients' QoL scores and major determinants were repeatedly assessed by construction of a mixed-effects model to adjust for possible confounders.Results: A total of 336 patients with 577 QoL measurements related to first-line anti-cancer treatments were enrolled. Performance status was the most important predictor of QoL scores in all domains after controlling for potential confounders. With age- and sex-matched healthy subjects as the reference, patients treated with gemcitabine + platinum showed significantly lower scores in multiple physical and psychological domain items in the WHOQOL-BREF. However, pemetrexed + platinum and gefitinib/erlotinib affected patients' QoL scores in 'energy/fatigue' and 'daily activities' with smaller magnitudes, and the scores appeared to improve after 3-4 months of treatment.Conclusions: Patients receiving gemcitabine + platinum as first-line anti-cancer treatment for advanced NSCLC experienced relatively poor QoL scores throughout treatment course. Studies to develop a real-time computerized system automatically updating the mixed-effects model for QoL to facilitate participatory clinical decision making by physicians, patients, and their families merit further research.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N